Tred, Of course things get extremely complicated during M&A's. If the tax plan is approved and the overseas corporate funds are repatriated, that is predicted to spur a great many M&A's. I believe that ANAVEX will be a prime target if we get positive results with Rett Syndrome trial and our other two trials have or are about to get started. Add to that the potential clinical development of 2-73 for M/S, and we may have a frenzy of suitors. Think this has been discussed by Biogen's BOD and they will have to consider a pre-emptive move on Anavex to protect their M/S market share and their attempt to enter the Alzheimer's drug arena with Aducanumab.
With the tempo picking up around the world due to the American Bio/Pharma's going on a shopping spree, the next 6 to12 months will produce a lot of fact and rumor. It should continue to bring volatility but with rising prices for small biotech.s with promising pipelines as the drug company market heats up. The mention of 3-71, 1-41, 1066 and 1037 highlighted in the 10K was done to draw attention to a strong and diverse pipeline for anyone looking. And IMHO there will more than a few companies looking
News 
Market Data 
Discover 
